Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Royal Bank of Canada (RY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Royal Bank of Canada — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while Royal Bank of Canada trades at $211.69 (market cap $292.49B). The key difference: Royal Bank of Canada is far larger — about 7.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Royal Bank of Canada pays a 2.42% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RY | |
|---|---|---|
Market Cap | $39.89B | $292.49B |
Sector | Health | Financials |
52-Week High | $491.22 | $211.09 |
52-Week Low | $278.09 | $128.46 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Royal Bank of Canada (RY) trades at $211.09, up 1.21% today, with a bullish technical signal and strong fundamental performance. Recent quarterly earnings consistently beat estimates, with Q1 2026 EPS of $2.84 exceeding the $2.81 forecast. Revenue grew to $66.53B in 2025, and net income margin improved to 31.85%. The company maintains a solid dividend, recently increasing it to $1.76 per share, and announced a share repurchase program.
RY's outlook is positive, supported by earnings momentum and shareholder returns, but faces risks from economic softness and high valuation multiples. Analyst sentiment is mixed, with a majority hold rating, reflecting caution amid rich valuations. The stock's current price near resistance at $211 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
